Medtronic (MDT) investor relations material

Business evolution and strategic direction

• Accelerated new product launches and portfolio actions, including the MiniMed IPO and renewed M&A activity, have driven business momentum over the past year.

• Confidence and positivity are high, with improved top-line performance and operational mechanisms now delivering results.

• Recent M&A, such as the Scientia acquisition, exemplifies the focus on synergistic, differentiated technologies that fill portfolio gaps and enhance commercial reach.

• Medium-sized tuck-in deals and ecosystem-building acquisitions are prioritized, with high financial return thresholds guiding business development.

Financial outlook and growth expectations

• Organic growth for fiscal 2026 is projected at 5.5%, with higher growth expected in 2027, excluding the 53rd week.

• High single-digit EPS growth is targeted for next year, with operational leverage from improved gross margins, pricing, and SG&A efficiency.

• M&A and the diabetes business separation will cause some dilution, but the 53rd week will help offset this at the EPS level.

Key business segments and innovation drivers

• Cardiac Ablation Solutions (CAS) has seen five consecutive quarters of accelerating growth, driven by Sphere-9 and upcoming Sphere-360 launches, with significant market runway remaining.

• PFA market penetration is currently 50-60%, expected to reach 80% in the next 12-24 months, with Sphere-9 and Sphere-360 providing strong differentiation.

• Renal denervation (Ardian) and Altaviva are early in commercialization, with large addressable markets and growing account openings, but will become more visible in 2027.

• TAVR business faces competitive pressures but is supported by new product iterations and investments in balloon-expandable valves and structural heart innovations.